06/08/2026 | Press release | Archived content
Boston, Massachusetts, June 8, 2026 - Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced positive Phase 2 clinical data for clofutriben, its lead investigational 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, in adults with Type 2 diabetes (T2D) at the 2026 Annual American Diabetes Association (ADA) Scientific Session.
In the intent-to-treat (ITT) population, clofutriben produced statistically significant improvements in HbA1c and total cholesterol. In a subset of patients with clinical features associated with a greater risk of having elevated cortisol, including inadequately controlled HbA1c despite treatment with two or more antidiabetic medications (EC-risk factor enriched), numerically larger improvements were observed across all cardiometabolic parameters, including HbA1c, glucose, total cholesterol, triglycerides, weight, and blood pressure. The data comes from a 6-week, randomized, double-blind, placebo- and active-controlled Phase 2 clinical trial (NCT02372578) originally intended to evaluate the effects of clofutriben on neuropathic pain in adults with T2D.
"These Phase 2 data reinforce our conviction that clofutriben could play an important role in improving not only glycemic control but also broad cardiometabolic dysfunction," said Robert Jacks, President & CEO of Sparrow Pharmaceuticals. "Clofutriben's novel mechanism targets cortisol, an often-overlooked driver of treatment resistance and disease progression, providing the potential to be a therapeutic option for patients whose needs are not addressed by current therapies. We are excited about our ongoing Phase 2b trial (CAPTAIN-T2D) evaluating clofutriben in patients with inadequately controlled T2D and EC and are planning for expansion into other high unmet need cardiometabolic indications."
Type 2 diabetes affects more than 37 million people in the U.S., and half of those are currently inadequately controlled. Furthermore, at least half of patients with difficult-to-control T2D have elevated cortisol at a level associated with increased cardiometabolic risk. Clofutriben is a potent and selective HSD-1 inhibitor that reduces intracellular cortisol in metabolically active tissues.
Key findings from the Phase 2 trial include:
Intent-to-treat population (N=75): Statistically significant placebo-adjusted reductions in HbA1c (−0.36%), glucose (-1.64 mM), and total cholesterol (−0.76 mM) were observed after 6 weeks of treatment with 10 mg clofutriben once daily.
EC risk factor-enriched subset (N=25; HbA1c ≥7.5% and ≥2 antidiabetic medications): Numerically larger improvements were seen across all parameters: HbA1c (−0.51%), glucose (−3.43 mM), total cholesterol (−1.17 mM), triglycerides (−0.86 mM), and weight (−1.3 kg), with small improvements in systolic (−2.4 mmHg) and diastolic (−1.3 mmHg) blood pressure also observed.
Safety: No clinically significant safety signals were observed in clinical laboratory measurements, vital signs, or electrocardiogram results. Thrombocytopenia was reported as a treatment-emergent serious adverse event in 1 patient randomized to clofutriben, who had an undisclosed history of idiopathic thrombocytopenic purpura, leading to trial discontinuation. The majority of adverse events (AEs) were mild or moderate in intensity.